85 %
of clinical trials are delayed1.
90 %
of target validations fail2.
95 %
of rare diseases lack approved treatment due to unknown gene-disease relationships3.
These tailored data analysis reports are generated in close consultation with biopharma partners and CENTOGENE’s in-house geneticists, medical experts, and data scientists. This seamlessly enables you to answer ad hoc research questions via real-world data, which is carefully curated, analyzed, and summarized by CENTOGENE’s team of experts.
CENTOGENE’s Biodatabank stands out globally for its unmatched genetic diversity, rich phenotypic data, and broad spectrum of rare and neurodegenerative diseases—empowering more precise and inclusive insights into human health. This heterogeneity of genomic variation has been informing our clinical interpretation and classification capabilities. The datasets reflect a diverse geographic and ethnic sample base and include a large share of rare and ultra-rare diseases, as well as pediatric cases. With over 1M patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent, CENTOGENE’s Biodatabank has contributed to generating novel insights for more than 350 peer-reviewed publications.
1M
~30,000
>120
The CENTOGENE Biodatabank reflects a diverse geographic and ethnic sample base and includes a large share of pediatric cases in rare and neurodegenerative diseases, with data modalities including clinical, multiomic, and socio-demographic data. By capturing diverse data, we establish a holistic view to enable the most accurate diagnosis and develop better disease models.
Our patients’ research consent allows us to also store data for 20 years – and with new genetic discoveries taking place every day, it is well placed to continue to accelerate the discovery and development of new biomarkers and targets well into the 21st century.
Dried blood spot (DBS) cards can be used to collect and ship patient samples. Serving as the simplest way to ship biological samples, CentoCard makes genetic testing available anywhere in the world.
We leverage AI to enhance the way we deal with patient samples. In doing so, we are able to automate variant prioritization, patient information extraction, data enrichment, and report automation with the highest levels of efficiency and accuracy.
With approximately 420 employees from more than 50 countries, we work with the best specialists to deliver data-driven solutions. Our team includes over 100 geneticists – delivering results you can trust by meticulously interpreting, reviewing, and approving genetic lab results.
Our global network of customer support and experts guiding you every step of the way.
Send us a messageRegional Support
